Our investigation of a vaccine consisting of an autologous brain tumor lysate mixed with CpG-containing oligonucleotides in an orthotopic mouse model of GBM revealed that while this therapy elicited initial CD8 T cell priming, the response generated was insufficient for tumor clearance [57]. This evidence concerns the gene CD8A and neoplasm.